Zanidatamab-Tislelizumab Regimen Reaches 27.0-Month Median OS in HERIZON-GEA-01 Gastric Cancer Trial
Start here
The Phase 3 HERIZON-GEA-01 trial, run by BeiGene, tested zanidatamab plus tislelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. At a second interim overall survival analysis, after a median follow-up of 35.3 months, the triple regimen achieved a median overall survival of 27.0 months versus 19.6 months in the control arm, with a hazard ratio of 0.65. The zanidatamab-plus-chemotherapy arm showed a median overall survival of 22.9 months (HR 0.76 versus control, P=0.0088). The difference between the tislelizumab-containing regimen and the zanidatamab-plus-chemotherapy arm did not reach statistical significance, leaving open the question of how much the PD-1 antibody adds.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comHERIZON-GEA-01 Phase 3: Zanidatamab Plus Tislelizumab and Chemotherapy Lifts Median OS to 27.0 Months in First-Line HER2-Positive Advanced Gastric Cancer
In the HERIZON-GEA-01 study, the zanidatamab plus tislelizumab plus chemotherapy arm achieved a median overall survival of 27.0 months in HER2-positive advanced gastroesophageal adenocarcinoma, with HR=0.65. The global multicenter phase 3 trial reported this second interim OS analysis after a median follow-up of 35.3 months; median OS was 19.6 months in the control arm and 22.9 months in the zanidatamab plus chemotherapy arm, HR=0.76, P=0.0088.
- mp.weixin.qq.comPickBeiGene HERIZON-GEA-01: Zanidatamab Plus Tislelizumab and Chemo Extends OS in HER2-Positive Gastroesophageal Adenocarcinoma, Difference Versus Zanidatamab Plus Chemo Not Significant
In the Phase 3 HERIZON-GEA-01 trial from BeiGene, zanidatamab combined with tislelizumab and chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma achieved a median overall survival of 27.0 months. The difference versus the zanidatamab plus chemotherapy group did not reach statistical significance.
Heat trend for this story
Not enough continuous observation yet to draw a trend.